Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety.

British journal of pharmacology - 1 Jun 2010

Samer C F, Daali Y, Wagner M, Hopfgartner G, Eap C B, Rebsamen M C, Rossier M F, Hochstrasser D, Dayer P, Desmeules J A

Abstract excerpt

BACKGROUND AND PURPOSE: The major drug-metabolizing enzymes for the oxidation of oxycodone are CYP2D6 and CYP3A. A high interindividual variability in the activity of these enzymes because of genetic polymorphisms and/or drug-drug interactions is well established. The possible role of an active metabolite in the pharmacodynamics of oxycodone has been questioned and the importance of CYP3A-mediated effects on the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Analgesics, Opioid
Share to Cross-Over Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6 Inhibitors

Share to Cytochrome P-450 CYP3A Inhibitors

Share to Double-Blind Method

Share to Drug Interactions

Share to Pain Threshold

Share to Psychomotor Performance

Source

Open in PubMed Open full text

Identifiers

PMID: 20590588
DOI: 10.1111/j.1476-5381.2010.00709.x
PMCID: PMC2935998

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety.PMID 20590588Read ↗

The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.Semantic proximity Read ↗

Contribution of CYP2D6 Functional Activity to Oxycodone Efficacy in Pain Management: Genetic Polymorphisms, Phenoconversion, and Tissue-Selective MetabolismSemantic proximity Read ↗

Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.Semantic proximity Read ↗

The Hypoalgesic Effect of Oxycodone in Human Experimental Pain Models in Relation to the CYP2D6 Oxidation PolymorphismSemantic proximity Read ↗

CYP2D6 phenotypes and opioid metabolism: the path to personalized analgesia.Semantic proximity Read ↗

Do CYP2D6 genotypes affect oxycodone dose, pharmacokinetics, pain, and adverse effects in cancer?Semantic proximity Read ↗

Utilization of pharmacogenomics and therapeutic drug monitoring for opioid pain management.Semantic proximity Read ↗

CYP2D6 genotype can help to predict effectiveness and safety during opioid treatment for chronic low back pain: results from a retrospective study in an Italian cohortSemantic proximity Read ↗

CYP2D6 genotype dependent oxycodone metabolism in postoperative patients.Semantic proximity Read ↗

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone)Semantic proximity Read ↗

An Explorative Study of CYP2D6's Polymorphism in a Sample of Chronic Pain Patients.Semantic proximity Read ↗

Influence of Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 (CYP2D6) Polymorphisms on Pain Sensitivity and Clinical Response to Weak Opioid AnalgesicsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.